UPDATE 1-Gilead cancer immunotherapy wins U.S. approval with $373,000 price
October 18, 2017 at 18:40 PM EDT
Oct 18 (Reuters) - A new therapy for a type of lymphoma developed by Kite Pharma, which was acquired by Gilead Sciences Inc, won U.S. approval on Wednesday, marking the second approval for this potentially revolutionary approach to fighting cancer.
